Bispecific Antibodies

Subscribe to Selected New Research on Bispecific Antibodies

278 relevant articles (17 outcomes, 31 trials/studies) found for this Bio-Agent

Description: Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.

Also Known As:

Antibodies, Bispecific; Bispecific Monoclonal Antibodies; Antibodies, Bifunctional; Antibodies, Bispecific Monoclonal; Monoclonal Antibodies, Bispecific; Bifunctional Antibodies

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Valerius, T: 4 articles (08/2002 - 11/2000)
2.	Lum, Lawrence G: 3 articles (03/2006 - 01/2005)
3.	Bohlen, H: 3 articles (02/2001 - 01/2001)
4.	Manzke, O: 3 articles (02/2001 - 01/2001)
5.	Diehl, V: 3 articles (02/2001 - 01/2001)
6.	Kontermann, Roland E: 2 articles (08/2007 - 01/2005)
7.	Davol, Pamela A: 2 articles (01/2006 - 01/2005)
8.	Asano, Ryutaro: 2 articles (12/2005 - 04/2002)
9.	Lindhofer, H: 2 articles (07/2005 - 07/2001)
10.	Hollander, Nurit: 2 articles (10/2004 - 03/2003)

Related Diseases

1.	Neoplasms (Cancer) 09/01/1997 - "Designed to direct and enhance the body's immune response to specific tumours and pathogens, bispecific antibodies have shown promising results in Phase I and Phase II clinical trials, leading in some cases to complete or partial responses in cancer patients. " 03/08/2002 - "A number of bispecific antibodies against B-cell markers have been shown to be effective in vitro in mediating tumor cell lysis and in vivo in inhibiting tumor growth in animal models. " 01/05/1999 - "Finally, long-term-surviving animals showed improved survival after i.v. rechallenge with tumor cells, indicating that bispecific antibodies are capable of inducing long-lasting protective immunity." 07/01/2000 - "Initial experiences with bispecific antibodies demonstrate both the promise for and limitations of this anti-cancer strategy. " 04/21/2006 - "Both laboratory and early clinical studies to date have demonstrated that bispecific antibodies (BsAb) may have potentially significant application in cancer therapy. " Order ALL the reference details at left...
2.	Lymphoma (Lymphomas) 10/01/1995 - "In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma." 03/01/2002 - "Bispecific antibodies for lymphoma are also in early clinical testing. " 09/01/2000 - "Bispecific antibodies for lymphoma may also have a future role in lymphoma therapy. " 05/01/2000 - "Alternatively, bispecific antibodies and idiotypic vaccination strategies are used to target autologous T cells to eliminate lymphoma cells. " 12/15/1998 - "These polyclonal CTLs, targeted by the CD3x19 bispecific antibodies, can lyse CD19(+) B-lymphoma cells. " Order ALL the reference details at left...
3.	Hodgkin Disease (Hodgkin's Disease) 07/01/2001 - "Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting." 01/01/2000 - "Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease." 10/15/1999 - "CD16/CD30 bispecific monoclonal antibodies can induce remissions of Hodgkin's disease refractory to chemo- and radiotherapy. " 10/01/1998 - "Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease." 01/01/1996 - "Treatment of Hodgkin's disease with bispecific antibodies." Order ALL the reference details at left...
4.	Residual Neoplasm 07/01/2000 - "Bispecific antibodies (bsAb) are considered as promising tools for the elimination of disseminated tumour cells in a minimal residual disease situation. " 06/01/2003 - "Bispecific antibodies (BsAb) with specificity to both tumor cells and CD3 molecule were believed to be promising immunological tools for the therapy with minimal residual diseases by activating cytotoxic T cells. " 10/15/2001 - "Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal residual disease situation. " 07/01/2001 - "Bispecific monoclonal antibodies (bsAbs) are a promising immunotherapeutic option for treatment of cancer, especially in situations of minimal residual disease. " 02/15/2006 - "Trifunctional bispecific antibodies (TbsAbs) capable of cross-linking T lymphocytes, natural killer, and other FcgammaR-positive effector cells, via their Fc region, to the tumor cells may be applied together with adoptive allogeneic-cell therapy to maximize antitumor responses while acting on GVHD in patients with minimal residual disease." Order ALL the reference details at left...
5.	Ovarian Neoplasms (Ovarian Cancer) 03/15/2006 - "Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study." 03/15/2006 - "Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. " 03/15/2006 - "With enhancement by bispecific antibodies, the mean percent lysis in a 51Cr release assay of fresh ovarian cancer cells exposed to autologous CIK cells increased from 21.7 +/- 0.3% to 89.4 +/- 2.1% at an E:T ratio of 100:1 (P < 0.001). " 01/01/1991 - "An evaluation of the efficacy of PBMC from ovarian cancer patients as effector cells revealed that their specific cytotoxicity against OVCAR-3 cells was enhanced severalfold by bispecific antibodies as compared to parental antibodies. " 01/01/1991 - "In addition, we have constructed bispecific monoclonal antibodies (BiMoAbs) directed against both the CD3/TCR complex (or the CD16 molecule) and a tumor associated antigen expressed on the surface of ovarian cancer cells. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antibodies
2.	Antigens
3.	IgG Receptors (Fc gamma RI)
4.	CD30 Antigens
5.	Immunoglobulin G (IgG)
6.	Immunotoxins (Immunotoxin)
7.	Monoclonal Antibodies
8.	Granulocyte Colony-Stimulating Factor (G-CSF)
9.	saporin
10.	Epidermal Growth Factor Receptor (EGF Receptor)

Related Therapies and Procedures

1.	Immunotherapy
2.	Therapeutics
3.	Heterologous Transplantation (Xenotransplantation)
4.	Radioimmunotherapy
5.	Boron Neutron Capture Therapy

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>